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Background. Rotavirus is the most common causes of severe, acute diarrhea during childhood and is an 
important cause of morbidity and mortality in developing countries. We established active hospital-based sur­
veillance of childhood diarrhea to assess the scope of severe rotavirus disease in Iran. 
Methods. From May 2006 through April 2007, prospective surveillance of rotavirus diarrhea among children 
aged !5 years was conducted in 5 sentinel hospitals in Iran. Stool samples were tested for rotavirus using a 
commercially available enzyme immunoassay, and rotavirus-positive samples were genotyped using reverse-tran­
scriptase polymerase chain reaction. 
Results. Of 2198 children admitted to the hospital for acute gastroenteritis, 1298 (59.1%) had stool samples 
test positive for rotavirus by enzyme immunoassay. Of the rotavirus episodes, 85% occurred during the ﬁrst 2 
years of life, with the peak prevalence of severe rotavirus disease occurring from September through January. 
Among the 110 rotavirus-positive samples that were genotyped, G4P[8] was the most commonly detected rotavirus 
genotype (30.9% of strains). Other commonly detected genotypes included P[8] with G nontypeable (21.8%), G4 
with P nontypeable (13.6%), G1[P8] (10.9%), and G2[P4] (5.5%). 
Conclusions. Rotavirus is the most common cause of severe diarrhea in Iran, which indicates that safe and 
effective rotavirus vaccination in Iran is a public health priority. 
In recent years, rotavirus has been recognized as one 
of the most common causes of severe acute diarrhea 
during childhood worldwide [1–4]. In both developed 
and developing countries, approximately one-third of 
all children admitted to hospitals with diarrhea are in­
fected with rotavirus [1, 3, 4]. In Iran, rotavirus infec-
tion is rarely diagnosed, and most physicians and public 
health professionals are unaware of its importance. Di­
rected efforts to increase awareness among pediatri­
cians, public health scientists, and key public health 
decision makers are critical to increase the likelihood 
of the introduction of the new-generation rotavirus vac­
cines in Iran [5–7]. 
The objective of the present surveillance project was 
to assess the burden of severe rotavirus disease in Iran 
through active hospital-based surveillance of diarrhea. 
These data will allow for accurate estimates of the num­
bers of rotavirus disease–related hospitalizations, clinic 
visits, and deaths in Iran and will be an invaluable aid 
to policy makers in Iran for evaluation of the potential 
health and economic beneﬁts of rotavirus vaccines. 
MATERIALS AND METHODS 
Surveillance sites and methods. We established hos-
pital-based surveillance of diarrhea at 5 sentinel hos­
pitals in the northern (Tabriz and Mashhad), central 
(Tehran), and southern (Shiraz and Bandar Abbas) 
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Table 1. Hospitalized Children Aged !5 Years with Rotavirus Gastroenteritis, by Location in Iran, 1 May 2006–30 April 2007 
Children with rotavirus-
No. of children with 
positive specimensa 
stool specimens 
Location Hospital screened No. Percentage (95% CI) 
Tabriz, Azarbayejan Sharghi Province Tabriz Pediatric Center 227 111 49.0 (42.2–55.6) 
Mashhad, Khorasan Razavi Province Dr. Sheikh Hospital 269 133 49.4 (43.3–55.6) 
Subtotal (northern region of Iran) … 496 244 49.2 (44.7–53.7) 
Shiraz, Fars Province Shahid Dastgheyb 825 547 66.3 (63.0–69.5) 
Bandarabbas, Hormozgan Province Bandarabbas Pediatric Center 627 397 63.3 (59.4–67.1) 
Subtotal (southern region of Iran) … 1452 944 65.0 (62.6–67.5) 
Tehran, Tehran Province Tehran Pediatric Center 250 110 44.0 (37.8–50.4) 
All locations … 2198 1298 59.1 (57.0–61.1) 
NOTE. CI, conﬁdence interval. 
a Stool specimens that tested positive by enzyme immunoassay. 
regions of Iran. These hospitals are among the largest health 
care facilities in the country and have catchment populations 
of ∼2,000,000 children (∼30.5% of Iranian children aged !5 
years). 
Surveillance methodology. From 1 May 2006 through 30 
April 2007, we attempted to enroll all children aged !5 years 
who were hospitalized overnight for diarrhea. Pediatricians 
were asked to notify a member of the surveillance team, who 
also reviewed daily admission logs to ensure that all eligible 
children were offered enrollment. A case report form that doc­
umented demographic, clinical, and laboratory information 
was completed, and a stool specimen was obtained to establish 
a diagnosis. The criteria for inclusion of children in the present 
surveillance were determined in accordance with a standard 
World Health Organization (WHO) case deﬁnition [8]. Gas­
troenteritis was deﬁned by the passing of �3 liquid or semi-
liquid stools and/or vomiting �2 times within a 24-h period. 
We included for analysis only those children from whom a 
stool specimen was obtained after enrollment. 
Analysis of stool samples. Stool specimens of 5 mL were 
collected in a screw-top container and were tested for the pres­
ence of rotavirus and enteric adenoviruses at the national lab­
oratory in Iran by enzyme immunoassay (Dakocytomation) in 
accordance with the manufacturer’s instructions. To examine 
the distribution of rotavirus strains in circulation, we selected 
a representative sample of 2 rotavirus specimens from each site 
weekly and characterized their G genotype (G1, G2, G3, G4, 
and G9) and P genotype (P[4], P[6], P[8], P[10], and P[11]) 
by reverse-transcriptase polymerase chain reaction (RT-PCR), 
in accordance with methods published elsewhere [9, 10]. For 
quality-control purposes, 145 (6.6%) of 2198 specimens were 
sent for conﬁrmation to the WHO Eastern Mediterranean Re­
gional Ofﬁce Rotavirus Reference Center in Cairo, Egypt. Of 
these 145 samples, 7 tested positive in Iran but tested negative 
at the reference laboratory, whereas 4 tested negative in Iran 
but tested positive at the reference laboratory. 
Statistical analysis. Statistical analysis was conducted using 
SPSS, version 15 (SPSS). Ethics committee approval was ob­
tained from the ethics committee at the Ministry of Health in 
Iran, and informed consent was obtained from a parent or 
guardian before patient enrollment. 
RESULTS 
During the 1-year surveillance period, a total of 2198 children 
aged !5 years with acute gastroenteritis were admitted to the 
5 sentinel hospitals and provided a stool sample. Of these 2198 
children, 1298 (59.1%) had samples test positive for rotavirus 
(Table 1). The percentage of rotavirus diarrhea–associated hos­
pitalizations varied among surveillance sites, with the highest 
percentage identiﬁed in Shiraz (66.3%) and the lowest in Tehran 
(44.0%). 
The age distribution of patients indicated that a vast majority 
(85.0%) of the rotavirus hospitalizations occurred before age 
Figure 1. Age distribution of the 1298 children aged !5 years who 
were hospitalized with rotavirus (RV) gastroenteritis at 5 sentinel hospitals 
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Figure 2. Monthly incidence of hospitalization among rotavirus (RV)– 
positive or RV-negative children aged !5 years at 5 sentinel hospitals in 
Iran, 1 May 2006–30 April 2007. 
2 years: 10% of the cases occurred in children aged 0–5 months, 
35% in children aged 6–11 months, and 40% in children aged 
12–23 months (Figure 1). A seasonal pattern of increase in 
hospitalizations for rotavirus disease was noted from September 
through February, with the peak number of cases occurring in 
January (Figure 2). 
Genotyping for G (VP7) and P (VP4) types was performed 
for 110 specimens (Table 2). The most common G serotype 
was G4 (44.5%), and 36.4% of strains were G nontypeable. Of 
the 110 specimens, 71 (64.5%) were characterized as P[8], 7 
(6.4%) as P[4], and 1 (0.9%) as P[9]; 31 (28.2%) were P non­
typeable. The predominant strain was G4P[8], representing 34 
(30.9%) of all characterized samples; other dominant strains 
were P[8] with G nontypeable (21.8%), G4 with P nontypeable 
(13.6%), G1[P8] (10.9%), and G2[P4] (5.5%) (Table 2). 
DISCUSSION 
Our ﬁndings indicate that rotavirus is the most important cause 
of severe diarrhea among hospitalized children aged !5 years 
in Iran. Through robust hospital-based surveillance of diarrhea 
at 5 large pediatric hospitals in Iran, we have demonstrated 
that rotavirus disease accounts for more than one-half of all 
hospitalizations for severe diarrhea among the surveillance pop­
ulation. Our data provide support for strong consideration of 
the introduction of recently available, safe, and effective rota-
virus vaccines in Iran. Given that children aged 6–24 months 
have the highest burden of severe rotavirus disease, the new 
rotavirus vaccines, which are administered in 2 or 3 doses before 
age 6–8 months, have the potential to substantially reduce a 
vast portion of the burden of severe rotavirus disease in children 
aged !5 years. In addition to prevention of hospitalizations, 
the greatest beneﬁt of these vaccines might be from reduction 
of the estimated 750–800 rotavirus-related deaths that occur 
annually in Iran [1]. 
Consideration of the introduction of a rotavirus vaccine rests 
in part on having accurate estimates of rotavirus disease burden. 
In a previous study conducted in southwest Iran, the prevalence 
of rotavirus, as examined by electron microscopy, was 11% 
[11]. However, rotavirus in our surveillance was detected using 
the more sensitive methods of enzyme immunoassay and RT­
PCR, which is likely the reason for the higher detection rates. 
In addition, our network included 5 surveillance sites, to obtain 
reasonable representation of the range of rotavirus disease bur­
den across sites. Thus, we are conﬁdent that our surveillance 
results better reﬂect the rotavirus burden in Iran than do pre­
vious estimates from smaller studies. 
Our data illustrate that rotavirus disease does have a seasonal 
component in Iran; however, even during the nonpeak months 
from March through August, rotavirus continued to account 
for ∼30% all hospitalizations for diarrhea. This is in contrast 
to ﬁndings in developed countries with temperate climates, 
where rotavirus infection has distinct winter seasonality with a 
notable absence of disease in the summer months [12]. In 
addition, the peak age at infection in Iran is similar to that in 
other countries where the greatest burden of disease occurs 
before age 2 years [2]. Reasons for differences in transmission 
patterns and how they relate to the epidemiology of rotavirus 
disease remain unclear but may have important implications 
for planning and monitoring the impact of rotavirus immu­
nization programs [13]. 
The predominant strain, G4P[8], represented 34 (31%) of 
all characterized strains during the surveillance year; however, 
we noted many nontypeable isolates. Two things may explain 
the relatively large number of nontypeable isolates. Sequence 
drift in the region of genotype-speciﬁc primer binding may 
have affected product ampliﬁcation. In countries of the WHO 
Eastern Mediterranean Region, this phenomena has recently 
been observed (authors’ unpublished data), similar to in other 
regions, where changes in the primary sequence has resulted 
in redesign of genotyping primers [14, 15]. The second possible 
Table 2. Frequency of Rotavirus Genotypes in Iran, 1 May 2006– 
30 April 2007 
No. (%) of strains with P type 
G type P[4] P[8] P[9] Nontypeable Total 
G1 … 12 (10.9) … … 12 (10.9) 
G2 6 (5.5) … … 1 (0.9) 7 (6.4) 
G3 … 1 (0.9) 1 (0.9) … 2 (1.8) 
G4 … 34 (30.9) … 15 (13.6) 49 (44.5) 
Nontypeable 1 (0.9) 24 (21.8) … 15 (13.6) 40 (36.4) 
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explanation is that the genotype-speciﬁc primers that we ap­
plied do not represent the currently circulating strains. We are 
in the process of obtaining DNA sequence data from the non­
typeable isolates in subsequent surveillance years, to address 
these issues. 
We acknowledge several limitations of our surveillance data. 
Because of Iran’s large population, we could not include sen­
tinel hospitals from every province. Thus, important popula­
tion segments or minority populations may not be represented 
in the 5 surveillance hospitals, particularly children in the poor­
est provinces, and these areas may have different disease burden 
or circulating strains. In border provinces, such as those near 
Pakistan and Afghanistan, more data are needed about disease 
epidemiology and genotype patterns, and more hospitals in 
these provinces should be included in future studies. Our strain 
typing results may not adequately reﬂect the circulating strains 
in Iran or at the surveillance hospitals, given the limited number 
of samples we typed. Future efforts to expand typing and to 
include a broader range of primers are underway, to address 
these limitations in future surveillance years. 
A high burden of rotavirus diarrheal disease among Iranian 
children has important implications for the consideration of 
prevention strategies through the routine immunization of chil­
dren. Although formal cost-effectiveness analyses would need 
to be conducted, given the success of the current vaccines dur­
ing clinical trials and routine postlicensure use, introduction 
of rotavirus vaccine could substantially improve child health 
in Iran [16–20]. By providing robust initial estimates of the 
rotavirus disease burden among children hospitalized with di­
arrhea, we hope to have begun the process of consideration of 
vaccine introduction in Iran. 
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